The development of polymerized pyridoxylated hemoglobin solution as a red cell substitute.
Development continues for a safe and effective hemoglobin solution to be used as a temporary red cell substitute. Our own efforts have progressed from the unmodified tetramer, to the pyridoxylated tetramer, to our current product--polymerized, pyridoxylated hemoglobin (Poly SFH-P). We recently completed two studies to evaluate the efficacy of Poly SFH-P. The results document that Poly SFH-P supports life in the absence of red cells while maintaining baseline hemodynamics and O2 consumption. In addition, Poly SFH-P achieves a near-normal plasma [Hb], and has a longer intravascular persistence than any unpolymerized product. Poly SFH-P thus is an improved red cell substitute for use in the clinical setting.
D000740:Anemia / Q000188:drug therapy; D000818:Animals; D001802:Blood Substitutes / Q000378:metabolism* / Q000627:therapeutic use; D004353:Drug Evaluation, Preclinical; D006400:Hematocrit; D006439:Hemodynamics; D006454:Hemoglobins / Q000378:metabolism* / Q000627:therapeutic use; D006801:Humans; D010101:Oxygen Consumption; D010215:Papio; D011732:Pyridoxal Phosphate / Q000031:analogs & derivatives* / Q000378:metabolism / Q000627:therapeutic use
D001802:Blood Substitutes; D006454:Hemoglobins; C030939:polyhemoglobin-pyridoxal-5-phosphate; D011732:Pyridoxal Phosphate